ライフサイエンスコーパス: seronegative

1 line (89.5% in seropositives versus 21.6% in seronegatives).

2 ropositive for NMDAR antibodies and 372 were seronegative.

3 er subdivided beyond simply seropositive and seronegative.

4 and by 3 months post-infection the bats are seronegative.

5 93 cases were seropositive and 67 cases were seronegative.

6 ease for individuals who are vaccinated when seronegative.

7 urrent with MOG antibodies, and 5 (10%) were seronegative.

8 omparable to those of subjects who were Ad26 seronegative.

9 hether the subjects were CMV seropositive or seronegative.

10 n high-risk donor CMV seropositive/recipient seronegative.

11 or with more symptoms were less likely to be seronegative.

12 firmed SARS-CoV-2 infection, 160 (6.3%) were seronegative.

13 ; these camels had a higher average age than seronegative.

14 The remaining 115 persons were seronegative.

15 ppressive medications were more likely to be seronegative (31.9%, 95% confidence interval [CI] 10.7%-

16 aporin-4 (AQP4)-Ab-seropositive, 3 double-Ab-seronegative, 4 myelin oligodendrocyte glycoprotein (MOG

17 ly higher among H. pylori seropositives than seronegatives 64% vs. 26% (p = 0.004); adjusted relative

18 In seronegative acute HIV infection, CD8(+) T cell counts i

19 tivity, was evident in the lamina propria of seronegative acutely HIV-infected patients.

20 iruses (MMRV) may cause severe infections in seronegative adult solid organ transplant (SOT) recipien

21 overall prevalence was 42%, with 28% in HIV-seronegative adults and 71% in HIV-seropositive adults (

22 We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-

23 Dec 10, 2010, and June 25, 2011, 11 897 HIV-seronegative adults were enrolled in SHIMS and 11 232 (9

24 greater risk for cardiovascular disease than seronegative adults.

25 Among PWID deemed seronegative after screening, there is no sustained tren

26 nts (PHIP) were enrolled, as well as 26 HCMV-seronegative and 39 HCMV-seropositive healthy controls.

27 re enrolled in the cohort, including 199 HIV seronegative and 99 HCV seronegative PWID.

28 HIV-1 envelop (Env) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers.

29 e 1 vaccine safety and immunogenicity in CMV-seronegative and CMV-seropositive adults.

30 viral therapy who were HSV-2 seropositive or seronegative and HIV-uninfected controls were analyzed b

31 We aimed to determine the proportion IgG seronegative and predictors for seronegativity among per

32 e for VCT; 1999 (24%) clients were initially seronegative and returned for another test.

33 MERS-CoV seronegative and seropositive camels received a single i

34 Genetic sharing between seronegative and seropostive RA (P < 1 x 10(-9)) had sig

35 tavirus IgA antibodies in subjects initially seronegative) and serum antirotavirus IgA titer, both co

36 One year after MMR3 receipt, no subject was seronegative, and 10 of 617 (1.6%) had low neutralizing

37 nth after MMR3 receipt, 1 subject (0.2%) was seronegative, and 6 (0.9%) had low neutralizing antibodi

38 more likely to be HPyV9-seropositive but MCV-seronegative, and HPyV7 seropositivity was associated wi

39 id not differ significantly in seropositive, seronegative, and statin-associated cases.

40 were also detected in Triplex-vaccinated CMV-seronegatives, and in DryVax-vaccinated subjects.

41 h NY15 was even greater in children who were seronegative at baseline (24 of 64 children [38%, 95% CI

42 7.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9

43 Of those seronegative at baseline, 3.6% seroconverted.

44 Among 493 participants who were seronegative at baseline, 482 (98%; 95% CI, 96 to 99) un

45 66.2% (49.1 to 77.5) in individuals who were seronegative at baseline, 90.4% (82.6 to 94.7) against h

46 in a G1P[8] rotavirus vaccine trial who were seronegative at baseline, anti-rotavirus immunoglobulin

47 cing seroconversion in participants who were seronegative at baseline.

48 In the BMCS, 1372 people were seronegative at baseline; 1259 (92%) had more than one f

49 Among 2535 patients seronegative at first antibody test, HCV incidence was 2

50 d from acutely symptomatic patients who were seronegative at presentation.

51 Most viraemic donors were seronegative at the time of donation.

52 ); in recipients who were Epstein-Barr virus-seronegative at the time of transplant and at risk of pr

53 739 women seronegative at their first pregnancy had at least one o

54 There were 739 women seronegative at their first pregnancy who had at least 1

55 Women seronegative at their first pregnancy with a subsequent

56 ve was to quantify, in a population of women seronegative at their first pregnancy, the risk of cCMV

57 sequent pregnancies in a population of women seronegative at their first pregnancy.

58 active IVDU donor who was hepatitis C virus seronegative at time of donation, but was found to be vi

59 In women seronegative before pregnancy, cCMV related sequelae are

60 In women seronegative before pregnancy, congenital cytomegaloviru

61 an infected baby was 4-fold higher in women seronegative before their pregnancy (P = .021).

62 1-year follow-up among patients who were HEV seronegative before transplantation, giving an annual in

63 ainst DENV-3 and DENV-4 in children who were seronegative before vaccination.

64 Subjects were most likely to become seronegative between 3 and 12 years postvaccination (log

65 We evaluated 500 seropositive and 300 seronegative blood donor plasma samples.

66 tients with suspected celiac disease who are seronegative but have villous atrophy and genetic risk f

67 starting ART before 12 weeks of age were HIV seronegative by almost 2 years of age.

68 At 1 day postinoculation, a seronegative calf (contact animal) was added to each of

69 Older seronegative camels responded more strongly to vaccinati

70 red to optimise vaccine regimens for younger seronegative camels.

71 a subgroup of seropositive-like cases within seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative

72 cluded in the differential diagnosis even in seronegative cases, although it is not typical for hydat

73 A diagnosis of seronegative celiac disease can then be confirmed based

74 se with selective IgA deficiency rather than seronegative celiac disease.

75 RSV-seronegative children aged 6-24 months received 1 intran

76 Respiratory syncytial virus-seronegative children ages 6-24 months received 1 intran

77 om an added gene was previously evaluated in seronegative children as a bivalent intranasal RSV/HPIV3

78 was previously shown to be well tolerated by seronegative children but was insufficiently immunogenic

79 spiratory syncytial virus (RSV) infection of seronegative children previously immunized with formalin

80 After a 2003 serosurvey, 130 originally seronegative children received one dose of virosomal HAV

81 dren and at 105 and 106 PFU in 21 and 30 RSV-seronegative children, respectively.

82 In RSV-seronegative children, the 105 PFU dose was overattenuat

83 ne that is attenuated yet immunogenic in RSV-seronegative children, warranting further evaluation.

84 RSV polymerase protein was evaluated in RSV-seronegative children.

85 zed, while the remaining 43 mothers had KSHV-seronegative children.

86 red in the management of patients with HBeAg-seronegative chronic hepatitis B.

87 49 probable and confirmed survivors and 157 seronegative contacts.

88 o probable and confirmed survivors and their seronegative contacts.

89 pants contributed 20 477 visits and 2808 HIV-seronegative control participants contributed 27 409 vis

90 s of celiac disease and age- and sex-matched seronegative controls (1:2).

91 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation

92 ts comprising antiretroviral-treated PWH and seronegative controls matched for age, body-mass index,

93 ADCC activity significantly higher than seronegative controls was detected in 24 of 68 KSHV-sero

94 g follow-up and 464 individually matched HIV-seronegative controls were selected from 5 cohorts of wo

95 , and 281 treated without SVR), and 2503 HCV-seronegative controls.

96 encephalitis, compared with activity in HIV-seronegative controls.

97 The number of patients with seronegative CRION and RION has decreased due to improve

98 isk donor CMV-seropositive and recipient CMV-seronegative (D+R-) liver transplant recipients in the c

99 ed in high-risk donor-seropositive/recipient-seronegative (D+R-) organ transplant recipients.

100 -14, and 15-22 months of age, the proportion seronegative decreased from 8.5% to 3.2%, 2.4%, and 1.5%

101 n areas of unmet need, including aquaporin-4 seronegative disease, and on development of treatments f

102 k is greatest in seropositive recipient (R+)/seronegative donor (D-) transplants and is exacerbated b

103 stimulation in vitro or engineered from HCV-seronegative donor T cells by transduction of a lentivir

104 higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .0

105 val as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.

106 otocol, our distribution of seropositive and seronegative donors and recipients was similar to the Un

107 Seropositive patients with seronegative donors did not have an increased risk of GV

108 T cells and MCs from CMV-seropositive or CMV-seronegative donors, and for antigen uptake.

109 ically infected patients, but not in healthy seronegative donors.

110 retory tissues of 44 CMV seropositive and 28 seronegative donors.

111 lts from serologic tests for celiac disease (seronegative enteropathy).

112 osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumatoid arthritis.

113 specific T cells were detectable in antibody-seronegative exposed family members and convalescent ind

114 mes of autoantibody-positive individuals and seronegative FDRs clustered together but separate from t

115 Furthermore, subjects with autoantibodies, seronegative FDRs, and new-onset patients had different

116 iversity were evident in seropositive versus seronegative FDRs.

117 re, 0 [range, 0-5]; P = .007), patients with seronegative findings (n = 28) (median visual score, 1.0

118 me that was similar to that of patients with seronegative findings.

119 SARS-CoV-2 convalescent individuals who were seronegative for anti-SARS-CoV-2 antibodies targeting sp

120 Patients with STM who were seronegative for AQP4-IgG among an Olmsted County popula

121 a, and VZV, respectively, and 165 (14%) were seronegative for at least one of the MMRV viruses.

122 A large proportion of SOT recipients were seronegative for at least one of the MMRV viruses.

123 d volunteers aged at least 45 years who were seronegative for HIV-1 from the established Ugandan Gene

124 lthy individuals (aged 18-45 years) who were seronegative for HIV-1.

125 %), 77 (6.5%), 65 (5.5%), and 22 (1.9%) were seronegative for measles, mumps, rubella, and VZV, respe

126 Of 662 subjects at baseline, 1 (0.2%) was seronegative for MeV-neutralizing antibodies (level, <8

127 Of the 107 serum pairs from infants who were seronegative for RV IgA at enrollment, we observed a str

128 RS-CoV-2 in 21 healthy donors (HDs) who were seronegative for SARS-CoV-2 and had no known exposure to

129 At month 84, in women seronegative for the corresponding HPV type in the accor

130 agic disease or ill from EEHV infection were seronegative for the EEHV species that caused the diseas

131 N9) virus hemagglutinins (HAs) despite being seronegative for these viruses in standard hemagglutinat

132 Of actual donors with IRB, 393 were seronegative for viral markers at time of donation.

133 on of titers among the participants who were seronegative for yellow fever antibody at baseline varie

134 y among patients ultimately determined to be seronegative for ZIKV and DENV by PRNT and alleviating s

135 samples from enrolled subjects who remained seronegative from both the placebo and active treatment

136 ean concentrations (GMCs) and the proportion seronegative (GMC <150 mIU/mL) were derived by age at fi

137 isk of new infection was lower compared to a seronegative group (hazard ratio adjusted 0.49, 95% CI 0

138 ate between the VGKC-complex subgroup versus seronegative group.

139 The features of seropositive versus seronegative groups were compared and binary logistic re

140 ears compared to 11% (1/9) of those who were seronegative (hazard ratio [HR], 8.2, P = .04).

141 stvaccination and higher in human CMV (HCMV)-seronegative (HCMV(-)) individuals than in HCMV-seroposi

142 er dose, we noted a seroconversion of 74% of seronegative HCWs.

143 ase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of as

144 A total of 223 anti-spike-seronegative health care workers had a positive PCR test

145 two and 28 urine samples from confirmed and seronegative healthy human subjects, respectively were i

146 Four CMV-seronegative healthy volunteers and three allogeneic HSC

147 resistance to HIV-1 infection in HIV-exposed seronegative (HESN) individuals is suggested to be assoc

148 occur both with PrEP initiation during acute seronegative HIV infection and in PrEP breakthrough infe

149 t evaluated the immunogenicity of MCVs among seronegative HIV-infected adults, measles seropositivity

150 een shown to be safe and immunogenic in HCMV-seronegative human subjects, eliciting both humoral and

151 Here, we demonstrate that seronegative immune repertoires contain antibodies that

152 ive value to rule out CD in patients who are seronegative in the face of histologic changes, in patie

153 um disorder patients (98 seropositive and 18 seronegative) in chronic disease phase and 65 age-, sex-

154 the infectiousness of HIV-seropositive and -seronegative index cases have been performed in sub-Saha

155 -B40 group was a risk factor for PTLD in EBV-seronegative individuals (OR = 8.38, 95% CI = 2.18-32.3)

156 ed alleles compared with 8 (28.6%) of the 28 seronegative individuals (P = .04).

157 censed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced d

158 unningham virus DNA was detected in urine of seronegative individuals in a research-grade assay.

159 Additional studies among HIV-seronegative individuals in clinics and community settin

160 (PrEP) by human immunodeficiency virus (HIV)-seronegative individuals reduces the risk of acquiring H

161 V-1-positive individuals and 136 HIV-exposed seronegative individuals were investigated for their ass

162 Eighteen HIV-1 infected HSV-2-seronegative individuals were randomly assigned in a dou

163 of a questionnaire at baseline and, for HIV-seronegative individuals, 6 months later.

164 ame-shifts mutations in the CCR5 gene in HIV seronegative individuals, as well as the well reported C

165 factors for PTLD in EBV-seropositive and EBV-seronegative individuals, respectively.

166 V-specific immune responses in HIV-1-exposed seronegative individuals.

167 arum lysate-seropositive individuals than in seronegative individuals.

168 safe development of nonlive RSV vaccines for seronegative infants and children.

169 any new RSV vaccine candidate developed for seronegative infants.

170 Among 119 HIV-seronegative inpatients, 46 (39%) had culture-positive p

171 In conclusion, among HIV-seronegative inpatients, CRP testing performed substanti

172 triage test for tuberculosis (TB) among HIV-seronegative inpatients.

173 ytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have be

174 HIV-exposed seronegative KIR3DS1 homozygotes have a reduced risk of

175 CMV seronegative kTx recipients were included.

176 Among CMV-seronegative liver transplant recipients with seropositi

177 therapy vs antiviral prophylaxis in 205 CMV-seronegative liver transplant recipients with seropositi

178 y of antiviral prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositi

179 ldren (88.2% HU and 95.8% HEU; P = .04) were seronegative (<150 mIU/mL) to measles at 4.2 months of a

180 response was defined as seroconversion from seronegative (<1:8) at baseline to seropositive (>1:8) a

181 response was defined as seroconversion from seronegative (<1:8) at baseline to seropositive (>=1:8)

182 investigation of RhCMV/SIV vaccines in RhCMV-seronegative macaques lacking anti-vector immunity.

183 Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral

184 bine-tenofovir disoproxil fumarate among HIV-seronegative men and transgender women who have sex with

185 ovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered persons who have sex

186 tal HSV shedding in HIV-seropositive and HIV-seronegative men and women in Uganda.

187 Each of 36 HCMV-seronegative men received 1 subcutaneous dose of 10, 100

188 e report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in transgende

189 nsgender women (p=0.31), and 58 (52%) of 111 seronegative MSM (p<0.0001).

190 In HIV-seronegative MSM, syphilis infection was associated with

191 Double-seronegative myasthenia gravis (dSNMG) includes patients

192 halitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMO

193 in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and

194 00%) were based on 92 control samples and 35 seronegative NMO/SD patient samples.

195 ly specific assays, leaving 35 patients with seronegative NMO/spectrum disorder (SD).

196 rs with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 cou

197 %, infectious type in 2%, sarcoidosis in 2%, seronegative NMOSD in 1%, and medication-related in 1%.

198 both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate thes

199 GFAP levels in some patients with double-Ab-seronegative NMOSD were markedly increased.

200 njury occurs in some patients with double-Ab-seronegative NMOSD, which hints at the possible existenc

201 We describe the establishment of a seronegative occult hepatitis B virus (HBV) infection (O

202 nts who cannot be clinically identified from seronegative ones.

203 Women were grouped as either HPV seronegative or having antibodies to 1-2 HPV types or to

204 on-imputed FRNT results classified as dengue seronegative or seropositive, the ELISA (with a 0.9 inde

205 Seronegative, parous women represent the highest risk po

206 We compared (1) HCV-seropositive with HCV-seronegative participants and (2) HCV-viremic with succe

207 ropositive and incidence density-matched HCV-seronegative participants of the Swiss HIV Cohort Study

208 e changes between HCV seroconverters and HCV-seronegative participants while adjusting for baseline c

209 cy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplificat

210 seropositive and 84 demographically-matched, seronegative participants, we examined serostatus and AD

211 articipants while it was only seen in 14% of seronegative participants.

212 ouples in which HIV-1 was transmitted to the seronegative partner during the study; control couples (

213 es in which HIV-1 was not transmitted to the seronegative partner.

214 of reperfusion compared with cytomegalovirus-seronegative patients (-192 versus -63 cells/muL; P=0.00

215 igher absolute eosinophil counts (AECs) than seronegative patients (P = .004).

216 symptom profiles and demographic features to seronegative patients but a shorter duration of psychosi

217 Eleven seropositive and 284 seronegative patients completed 4 weeks of amisulpride t

218 ulosis cases may be less infectious than HIV-seronegative patients only when they are smear-negative

219 By 2019, HCV-seronegative patients received the majority of kidneys t

220 d GFAP levels could identify those double-Ab-seronegative patients suitable to undergo in-depth autoi

221 tio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical pr

222 Some IgG-seronegative patients who receive an IgG-seropositive al

223 BEST PRACTICE ADVICE 7: Seronegative patients with an identified cause for enter

224 In seronegative patients with seropositive donors, the HR f

225 the infectiousness of HIV-seropositive and -seronegative patients with tuberculosis to their househo

226 ts can be used to rule out celiac disease in seronegative patients.

227 a classic picture of ALS, similar to that of seronegative patients.

228 donors with low levels i(4 of 30), and 0% of seronegative persons (0 of 32).

229 with low JCV serostatus (2 of 93), and 0% of seronegative persons (0 of 43).

230 s with undiagnosed celiac disease vs 0.1% in seronegative persons (P < .01).

231 HSV-specific CD4 T cells recovered from HSV-seronegative persons can be explained, in part, by such

232 Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receivi

233 valACV suppresses VL in HIV-1 infected HSV-2-seronegative persons.

234 he intestinal mucosal barrier already in the seronegative phase of acute HIV infection, thereby induc

235 t stages of HIV infection, starting from the seronegative phase.

236 ore samples from seropositive pigs than from seronegative pigs.

237 apid test to confirm TB diagnosis in the HIV-seronegative population.

238 early second trimester in two of three rhCMV-seronegative pregnant females.

239 V-associated sequelae occurred in four rhCMV-seronegative pregnant macaques that were CD4(+) T-cell d

240 has been placed on reducing transmission to seronegative pregnant women to prevent vertical transmis

241 The overall weighted seronegative prevalence of VZV was 2.2% for the pooled N

242 Initially HCV-seronegative PWID (n = 208) were followed prospectively

243 t, including 199 HIV seronegative and 99 HCV seronegative PWID.

244 seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative RA cases).

245 ation was found for sugar-sweetened soda and seronegative RA.

246 omplements the diagnosis for early stage and seronegative RA.

247 The proportion seronegative ranged from 0% among 79 persons previously

248 lant recipients (260 seropositive donor [D+]/seronegative recipient [R-] and 277 R+), CMV events occu

249 2 HHV8-mismatch patients (seropositive donor/seronegative recipient) developed a primary infection, o

250 PTLD and compare survival outcomes with EBV-seronegative recipients (R-).

251 Only 7 of 12 (58.3%) seronegative recipients of a seropositive donor (positiv

252 sponse in HCMV-seropositive (R+) LTRs and in seronegative recipients of positive organs (D+/R-).

253 Over time, HCV-seronegative recipients received a rising proportion of

254 ipients of kidney transplants, including 168 seronegative recipients receiving organs from seropositi

255 Among 308 CMV seronegative recipients, 168 CMV high-risk and 203 belat

256 When transplanted into HCV-seronegative recipients, HCV-viremic kidneys matched to

257 V-viremic kidneys were transplanted into HCV-seronegative recipients, versus 69 into HCV-seropositive

258 f transplanting HCV-viremic kidneys into HCV-seronegative recipients.

259 ation benefits both the whole population and seronegative recipients.

260 The proportion seronegative remained relatively stable among persons te

261 years, we observed (HCV seropositive and HCV seronegative, respectively) 107 and 18 liver events, 41

262 derly individuals, and occasionally leads to seronegative rheumatoid arthritis-like pathologies.

263 ed anti-Gag and anti-Env antibodies in RhCMV-seronegative RM, an unexpected contrast to vaccination o

264 Of 3990 initially seronegative samples, 3284 (82.3%) were seropositive aft

265 clusion chromatography, we obtained from HCV-seronegative sera a purified fraction enriched in inhibi

266 V PRNT-positive samples and in 12 of 22 PRNT-seronegative sera.

267 suggesting a major prevention benefit among seronegative sex partners in stable or casual relationsh

268 eviously symptomatic persons, the proportion seronegative slightly increased from 14 to 90 days post

269 iciency virus (HIV) participants compared to seronegative (SN) controls.

270 pients had seroreverted, and 63/111 (57%) of seronegative SOT recipients seroconverted for at least o

271 LISA showed >95% specificity in 22 ZIKV/DENV-seronegative specimens and in 13 samples positive for NA

272 flammatory disorders collectively termed the seronegative spondyloarthropathies (SpA) include ankylos

273 riables associated with DNAemia included EBV seronegative status at transplant (p = 0.045), non-White

274 ion-surveillance, proving clinical cases and seronegative status of FMDV-free/naive-animals prior tra

275 Epstein-Barr virus (EBV) seronegative status pretransplant (odds ratio [OR] = 7.6

276 er showed that sera from V160-immunized HCMV-seronegative subjects have attributes similar in quality

277 HIV-1-specific T-cell responses in exposed seronegative subjects suggest that a viral breach of the

278 genotype is more frequent among HIV-exposed seronegative subjects than among HIV-susceptible individ

279 apid local viral extinction due to a lack of seronegative subjects to maintain transmission chains fo

280 izing antibodies and T-cell responses in CMV-seronegative subjects were within ranges observed follow

281 cords and compared among 32 HIV-infected CMV-seronegative subjects, 126 age, CD4 and gender-matched H

282 en demonstrated safe and immunogenic in HCMV-seronegative subjects.

283 More specimens from the ART-96W group were seronegative than from the ART-Def group by enzyme immun

284 patients and control group participants were seronegative to IgA antibodies to TG2, endomysium, and d

285 The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot ar

286 at the seroconversion visit, six (18%) of 33 seronegative transgender women (p=0.31), and 58 (52%) of

287 household contacts of HIV-seropositive and -seronegative tuberculosis cases (relative risk, 0.89; 95

288 there was an excess risk of severe dengue in seronegative vaccinees.

289 body and modest CD4+ T-cell responses in HSV-seronegative vaccinees.

290 16 inoculum that can cause clinical colds in seronegative volunteers, and they also serve as a stable

291 he dose necessary to cause moderate colds in seronegative volunteers.

292 SCT patients, 29 349 seropositive and 20 193 seronegative, were identified from the European Group fo

293 re seen in patients when they became MOG-IgG seronegative, whereas a persistent positive serological

294 humans, even though the study subjects were seronegative with respect to the vaccine viruses before

295 oprotein (MOG)-Ab-seropositive and 4 AQP4-Ab-seronegative with unknown MOG-Ab-serostatus), multiple s

296 andidate vaccines have been shown to protect seronegative women and transplant recipients, and we sho

297 gy in all models, but in 1 model vaccinating seronegative women at 19-21 years of age was also optima

298 ually randomized superiority trial among HIV-seronegative women at three sites in Malawi with high SP

299 stablished risk factor of cCMV in previously seronegative women.

300 ort-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that endocrine disrup